Elekta AB’s stock has been under intense scrutiny this week, with conflicting recommendations from major financial institutions, including a sell recommendation from UBS and a revised hold recommendation from Deutsche Bank.

Financial analysts have adjusted their ratings for Elekta AB, a leading health care equipment company, to reflect a cautious outlook on the company’s stock due to slowing market growth and evolving market dynamics.

Deutsche Bank’s downgrade of Elekta AB’s target price from 63 SEK to 49 SEK has raised concerns about the company’s future trajectory and sparked a mixed reaction in the market.

Elekta AB’s credit outlook has been downgraded to negative by S&P Global Ratings due to elevated debt levels and weaker-than-expected cash flow.

Elekta AB’s Q4 2025 earnings report showed mixed results, with strong earnings overshadowed by concerns over order intake and the US market’s performance.

Elekta AB, a Swedish health care company, has demonstrated resilience and innovation in the sector, with a strong financial foundation and a clear vision for continued growth and leadership in cancer and brain disorder treatments.